Sujin Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sujin Yang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Dandan Wang
Department of Breast Surgery The First Affiliated Hospital with Nanjing Medical University Nanjing China
3 shared publicationsShan-Liang Zhong
The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, PR China
3 shared publicationsSi-Ying Zhou
Nanjing University of Chinese Medicine, Nanjing 210028, PR China
3 shared publicationsDan-Dan Wang
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, PR China
2 shared publicationsHe-Da Zhang
Department of General Surgery, Southeast University Medical School, Nanjing 210000, PR China
2 shared publicationsJian Li
Department of General Surgery, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Baiziting 42, Nanjing 210029, PR China
2 shared publications
Latest Publications
- Open Access
- 12 June 2025
- Published by Wiley in Cancer Science
- Vol. 116 (9) , 2547-2567
Engineered EVs‐Mediated miR‐222 Targeting PTEN/FN1 Axis Reverses Anthracycline Resistance in HER2‐Negative Breast Cancer
Anthracycline resistance represents a critical therapeutic challenge in breast cancer treatment, wherein alterations in the tumor immune microenvironment and enhanced cellular resistance mechanisms facilitate chemoresistance progression. Transcriptome analysis of 142 HER2‐negative breast cancer patients undergoing anthracycline‐based chemotherapy revealed four distinct tumor‐infiltrating cell subtypes, with subtype D exhibiting elevated M1 macrophage infiltration and superior prognostic outcomes. Differential expression analysis identified miR‐222 as the predominantly upregulated microRNA in adriamycin‐resistant cells, while Tandem Mass Tag mass spectrometry‐based quantitative analysis elucidated PTEN as its direct target and FN1 as a crucial downstream mediator. Engineered extracellular vesicles (EVs) carrying a miR‐222 inhibitor were developed to reverse adriamycin resistance via PTEN/FN1 signaling modulation. Molecular docking analysis found specific PTEN‐FN1 protein interactions characterized by stable hydrogen bonds at ARG142‐ASP23 and ARG15‐GLU95. In xenograft models, EVs‐mediated delivery of the miR‐222 inhibitor significantly attenuated MCF‐7/ADR tumor progression through miR‐222 suppression and PTEN restoration, with concordant molecular alterations observed in serum‐derived EVs. Our findings establish a novel mechanism of EVs‐mediated drug resistance through the microRNA‐222/PTEN/FN1 axis and present Engineered EVs as a promising therapeutic strategy for anthracycline resistance in breast cancer, while highlighting circulating EVs profiles as potential treatment monitoring biomarkers.
- 12 June 2025
- Published by Wiley in Cancer Science
- Vol. 116 (9) , 2547-2567
Open AccessEngineered EVs‐Mediated miR‐222 Targeting PTEN/FN1 Axis Reverses Anthracycline Resistance in HER2‐Negative Breast Cancer
Anthracycline resistance represents a critical therapeutic challenge in breast cancer treatment, wherein alterations in the tumor immune microenvironment and enhanced cellular resistance mechanisms facilitate chemoresistance progression. Transcriptome analysis of 142 HER2‐negative breast cancer patients undergoing anthracycline‐based chemotherapy revealed four distinct tumor‐infiltrating cell subtypes, with subtype D exhibiting elevated M1 macrophage infiltration and superior prognostic outcomes. Differential expression analysis identified miR‐222 as the predominantly upregulated microRNA in adriamycin‐resistant cells, while Tandem Mass Tag mass spectrometry‐based quantitative analysis elucidated PTEN as its direct target and FN1 as a crucial downstream mediator. Engineered extracellular vesicles (EVs) carrying a miR‐222 inhibitor were developed to reverse adriamycin resistance via PTEN/FN1 signaling modulation. Molecular docking analysis found specific PTEN‐FN1 protein interactions characterized by stable hydrogen bonds at ARG142‐ASP23 and ARG15‐GLU95. In xenograft models, EVs‐mediated delivery of the miR‐222 inhibitor significantly attenuated MCF‐7/ADR tumor progression through miR‐222 suppression and PTEN restoration, with concordant molecular alterations observed in serum‐derived EVs. Our findings establish a novel mechanism of EVs‐mediated drug resistance through the microRNA‐222/PTEN/FN1 axis and present Engineered EVs as a promising therapeutic strategy for anthracycline resistance in breast cancer, while highlighting circulating EVs profiles as potential treatment monitoring biomarkers.
- Open Access
- 1 November 2024
- Published by KEAI Publishing in Genes & Diseases
- Vol. 11 (6) , 101176
HJURP indicates poor prognosis of female breast cancer by promoting cell proliferation and migration
- 1 November 2024
- Published by KEAI Publishing in Genes & Diseases
- Vol. 11 (6) , 101176
Open AccessHJURP indicates poor prognosis of female breast cancer by promoting cell proliferation and migration
- 19 December 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 963, 176221
circNFIB decreases synthesis of arachidonic acid and inhibits breast tumor growth and metastasis
- 19 December 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 963, 176221
circNFIB decreases synthesis of arachidonic acid and inhibits breast tumor growth and metastasis
- 22 January 2020
- Published by Wiley in Journal of Cellular Physiology
- Vol. 235 (7-8) , 5722-5735
Microenvironment‐induced TIMP2 loss by cancer‐secreted exosomal miR‐4443 promotes liver metastasis of breast cancer
We aimed to investigate the role of exosomal miR‐4443 in metastasis of breast cancer (BCa). In vitro wound‐healing assay and transwell invasion assay were used to investigate effect of miR‐4443 on BCa cells. Animal experiments were performed to confirm its effects in vivo. miR‐4443 promotes the metastasis of BCa cells through downregulating tissue inhibitors of metalloproteinase 2 (TIMP2) and upregulating matrix metalloproteinases (MMPs). Highly invasive BCa cells have a higher expression of miR‐4443 in both cells and exosomes. The exosomes derived from highly invasive BCa cells mainly gather in the primary tumor and liver. In vivo, overexpression of miR‐4443 in noninvasive BCa cells induces liver metastasis, accompanied with downregulated TIMP2, and upregulated MMP‐2 in both the primary tumor and liver. When we armed MCF‐10A exosomes with miR‐4443 inhibitors to treat mice bearing high‐miR‐4443 tumors, exosomes accumulated in the primary tumor, and liver following the upregulation of TIMP2 and downregulation of MMP2, and the metastasis was inhibited. Highly invasive BCa cells destroy natural barriers against metastasis by delivering exosomal miR‐4443 to stromal cells of the primary tumor and impairing TIMP2, consequently activating MMP; circulating exosomal miR‐4443 might promote BCa cells lodging in future metastatic sites through the similar mechanisms.
- 22 January 2020
- Published by Wiley in Journal of Cellular Physiology
- Vol. 235 (7-8) , 5722-5735
Microenvironment‐induced TIMP2 loss by cancer‐secreted exosomal miR‐4443 promotes liver metastasis of breast cancer
We aimed to investigate the role of exosomal miR‐4443 in metastasis of breast cancer (BCa). In vitro wound‐healing assay and transwell invasion assay were used to investigate effect of miR‐4443 on BCa cells. Animal experiments were performed to confirm its effects in vivo. miR‐4443 promotes the metastasis of BCa cells through downregulating tissue inhibitors of metalloproteinase 2 (TIMP2) and upregulating matrix metalloproteinases (MMPs). Highly invasive BCa cells have a higher expression of miR‐4443 in both cells and exosomes. The exosomes derived from highly invasive BCa cells mainly gather in the primary tumor and liver. In vivo, overexpression of miR‐4443 in noninvasive BCa cells induces liver metastasis, accompanied with downregulated TIMP2, and upregulated MMP‐2 in both the primary tumor and liver. When we armed MCF‐10A exosomes with miR‐4443 inhibitors to treat mice bearing high‐miR‐4443 tumors, exosomes accumulated in the primary tumor, and liver following the upregulation of TIMP2 and downregulation of MMP2, and the metastasis was inhibited. Highly invasive BCa cells destroy natural barriers against metastasis by delivering exosomal miR‐4443 to stromal cells of the primary tumor and impairing TIMP2, consequently activating MMP; circulating exosomal miR‐4443 might promote BCa cells lodging in future metastatic sites through the similar mechanisms.
- 10 January 2020
- Published by Taylor & Francis in Epigenomics
- Vol. 12 (2) , 101-125
Identification of CircRNA–miRNA Networks for Exploring an Underlying Prognosis Strategy for Breast Cancer
Aim: Circular RNAs (circRNAs) still have many potential functions in the process of tumor development that are not completely understood. The study aims to explore novel circRNAs and their mechanis...
- 10 January 2020
- Published by Taylor & Francis in Epigenomics
- Vol. 12 (2) , 101-125
Identification of CircRNA–miRNA Networks for Exploring an Underlying Prognosis Strategy for Breast Cancer
Aim: Circular RNAs (circRNAs) still have many potential functions in the process of tumor development that are not completely understood. The study aims to explore novel circRNAs and their mechanis...
- 10 January 2020
- Published by Taylor & Francis in Epigenomics
- Vol. 12 (4) , 303-317
Circular RNA CircVAPA Regulates Breast Cancer Cell Migration and Invasion Via Sponging miR-130a-5p
Aim: We aimed to explore the roles of circular RNA, circVAPA in regulating cell migration and invasion of breast cancer. Materials & methods: CircVAPA expression was detected in breast cancer tissues and cells. The role of circVAPA was evaluated by MTT assay, wound-healing and transwell assay. The relationship between circVAPA and miR-130a-5p and the location of circVAPA were explored. Results: We discovered that circVAPA was dysregulated in breast cancer tissues and cells. Ectopic circVAPA regulated breast cancer migration, invasion and proliferation. CircVAPA was mainly expressed in the cytoplasm and could act as a miRNA sponge for miR-130a-5p, but did not regulate its parental gene. Conclusion: CircVAPA may promote migration and invasion capacity of breast cancer via harboring miR-130a-5p.
- 10 January 2020
- Published by Taylor & Francis in Epigenomics
- Vol. 12 (4) , 303-317
Circular RNA CircVAPA Regulates Breast Cancer Cell Migration and Invasion Via Sponging miR-130a-5p
Aim: We aimed to explore the roles of circular RNA, circVAPA in regulating cell migration and invasion of breast cancer. Materials & methods: CircVAPA expression was detected in breast cancer tissues and cells. The role of circVAPA was evaluated by MTT assay, wound-healing and transwell assay. The relationship between circVAPA and miR-130a-5p and the location of circVAPA were explored. Results: We discovered that circVAPA was dysregulated in breast cancer tissues and cells. Ectopic circVAPA regulated breast cancer migration, invasion and proliferation. CircVAPA was mainly expressed in the cytoplasm and could act as a miRNA sponge for miR-130a-5p, but did not regulate its parental gene. Conclusion: CircVAPA may promote migration and invasion capacity of breast cancer via harboring miR-130a-5p.